Who are OROS hydromorphone HCL ; OxyContin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SAMIDORPHAN L-MALATE, BENZHYDROCODONE, NALBUPHINE HYDROCHLORIDE, Methadone Hydrochloride, dexketoprofen trometamol + pethidine hydrochloride, Suboxone (SCH 000484).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oros-hydromorphone-hcl-oxycontin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

OROS hydromorphone HCL ; OxyContin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OROS hydromorphone HCL ; OxyContin (OROS hydromorphone HCL ; OxyContin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: opioid analgesic. Area: Pain management.

phase 3 opioid analgesic opioid receptors Pain management Small molecule Live · refreshed every 30 min

Target snapshot

OROS hydromorphone HCL ; OxyContin (OROS hydromorphone HCL ; OxyContin) — Alza Corporation, DE, USA. OROS hydromorphone HCL is a long-acting opioid analgesic that works by binding to opioid receptors in the brain, spinal cord, and other areas of the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OROS hydromorphone HCL ; OxyContin TARGET	OROS hydromorphone HCL ; OxyContin	Alza Corporation, DE, USA	phase 3	opioid analgesic	opioid receptors
SAMIDORPHAN L-MALATE	SAMIDORPHAN L-MALATE		marketed	Atypical Antipsychotic [EPC]	dopamine and serotonin type 2 (5HT2) receptors, opioid receptors	2021-01-01
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
dexketoprofen trometamol + pethidine hydrochloride	dexketoprofen trometamol + pethidine hydrochloride	Kavaklıdere Umut Hospital	marketed	["NSAID", "opioid analgesic"]	["cyclooxygenase (COX) enzymes", "mu-opioid receptors"]
Suboxone (SCH 000484)	Suboxone (SCH 000484)	Merck Sharp & Dohme LLC	marketed	Opioid agonist-antagonist combination	Mu-opioid receptor (buprenorphine); opioid receptors (naloxone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (opioid analgesic class)

· 1 drug in this class
Alza Corporation, DE, USA · 1 drug in this class
Cephalon · 1 drug in this class
INSYS Therapeutics Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OROS hydromorphone HCL ; OxyContin — Competitive Intelligence Brief. https://druglandscape.com/ci/oros-hydromorphone-hcl-oxycontin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab